<?xml version='1.0' encoding='utf-8'?>
<document id="31526233"><sentence text="MicroRNA Mediated Changes in Drug Metabolism and Target Gene Expression by Efavirenz and Rifampicin In Vitro: Clinical Implications."><entity charOffset="75-84" id="DDI-PubMed.31526233.s1.e0" text="Efavirenz" /><entity charOffset="89-99" id="DDI-PubMed.31526233.s1.e1" text="Rifampicin" /><pair ddi="false" e1="DDI-PubMed.31526233.s1.e0" e2="DDI-PubMed.31526233.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31526233.s1.e0" e2="DDI-PubMed.31526233.s1.e1" /></sentence><sentence text="Efavirenz (EFV) and rifampicin (RMP) are widely prescribed in Africa for treatment of HIV/AIDS and tuberculosis epidemics"><entity charOffset="0-9" id="DDI-PubMed.31526233.s2.e0" text="Efavirenz" /><entity charOffset="11-14" id="DDI-PubMed.31526233.s2.e1" text="EFV" /><entity charOffset="20-30" id="DDI-PubMed.31526233.s2.e2" text="rifampicin" /><entity charOffset="32-35" id="DDI-PubMed.31526233.s2.e3" text="RMP" /><pair ddi="false" e1="DDI-PubMed.31526233.s2.e0" e2="DDI-PubMed.31526233.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31526233.s2.e0" e2="DDI-PubMed.31526233.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31526233.s2.e0" e2="DDI-PubMed.31526233.s2.e2" /><pair ddi="false" e1="DDI-PubMed.31526233.s2.e0" e2="DDI-PubMed.31526233.s2.e3" /><pair ddi="false" e1="DDI-PubMed.31526233.s2.e1" e2="DDI-PubMed.31526233.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31526233.s2.e1" e2="DDI-PubMed.31526233.s2.e2" /><pair ddi="false" e1="DDI-PubMed.31526233.s2.e1" e2="DDI-PubMed.31526233.s2.e3" /><pair ddi="false" e1="DDI-PubMed.31526233.s2.e2" e2="DDI-PubMed.31526233.s2.e2" /><pair ddi="false" e1="DDI-PubMed.31526233.s2.e2" e2="DDI-PubMed.31526233.s2.e3" /></sentence><sentence text=" Exposure to medicines can alter drug metabolism, for example, through changes in expression of microRNAs" /><sentence text=" We report, in this study, novel observations on the ways in which EFV and RMP change microRNA expression signatures in vitro in HepaRG cells"><entity charOffset="67-69" id="DDI-PubMed.31526233.s4.e0" text="EFV" /><entity charOffset="75-77" id="DDI-PubMed.31526233.s4.e1" text="RMP" /><pair ddi="false" e1="DDI-PubMed.31526233.s4.e0" e2="DDI-PubMed.31526233.s4.e0" /><pair ddi="false" e1="DDI-PubMed.31526233.s4.e0" e2="DDI-PubMed.31526233.s4.e1" /></sentence><sentence text=" Additionally, we discuss the clinical implications of changes in expression of drug-metabolizing enzyme genes, such as CYP3A4, CYP3A5, UGT1A1, CYP2B6, and NR1I3" /><sentence text=" Differentiated HepaRG cells were treated with EFV (6"><entity charOffset="47-49" id="DDI-PubMed.31526233.s6.e0" text="EFV" /></sentence><sentence text="4 μM) or RMP (24"><entity charOffset="9-11" id="DDI-PubMed.31526233.s7.e0" text="RMP" /></sentence><sentence text="4 μM) for 24 h" /><sentence text=" Treatment of HepaRG cells with EFV resulted in a significant increase in messenger RNA (mRNA) expression for CYP3A4 (12"><entity charOffset="32-34" id="DDI-PubMed.31526233.s9.e0" text="EFV" /></sentence><sentence text="51-fold, p = 0" /><sentence text="002), CYP3A5 (2" /><sentence text="10-fold, p = 0" /><sentence text="019), and UGT1A1 (2" /><sentence text="52-fold, p = 0" /><sentence text="005), whereas NR1I3 expression decreased (0" /><sentence text="41-fold, p = 0" /><sentence text="02)" /><sentence text=" On the other hand, treatment of HepaRG cells with RMP resulted in a significant increase in mRNA expression for CYP2B6 (6"><entity charOffset="51-53" id="DDI-PubMed.31526233.s18.e0" text="RMP" /></sentence><sentence text="68-fold, p = 0" /><sentence text="007) and CYP3A4 (111" /><sentence text="96-fold, p = 0" /><sentence text="001), whereas NR1I3 expression decreased (0" /><sentence text="46-fold, p = 0" /><sentence text="033)" /><sentence text=" These data point to several important clinical implications through changes in drug/drug interaction risks and achieving optimal therapeutics" /><sentence text=" All in all, this study shows that differential expression of microRNAs after treatment with EFV and RMP adds another layer of complexity that should be incorporated in pharmacogenomic algorithms to render drug response more predictable"><entity charOffset="93-95" id="DDI-PubMed.31526233.s26.e0" text="EFV" /><entity charOffset="101-103" id="DDI-PubMed.31526233.s26.e1" text="RMP" /><pair ddi="false" e1="DDI-PubMed.31526233.s26.e0" e2="DDI-PubMed.31526233.s26.e0" /><pair ddi="false" e1="DDI-PubMed.31526233.s26.e0" e2="DDI-PubMed.31526233.s26.e1" /></sentence><sentence text="" /></document>